Home » FDA Approves Labeling Change for Vyvanse Capsules
FDA Approves Labeling Change for Vyvanse Capsules
Shire Tuesday announced that the US Food and Drug Administration (FDA) approved a change
to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment Vyvanse (lisdexamfetamine dimesylate) Capsules
CII.
Benzinga
Benzinga
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May